Eloine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eloine

Quick Facts

Property Description
Active Ingredients Drospirenone and Ethinyl Estradiol
Form Film-coated tablets
Pharmacological Class Progestogens with Oestrogens / Combined Hormonal Contraceptive (CHC)
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic hormone combination

What Type of Medicine is Eloine and What is Its Purpose?

Eloine is a prescription-only medication classified as a Combined Oral Contraceptive (COC), whose primary purpose is to provide highly effective pregnancy prevention for women of reproductive age. It belongs to the pharmacological class of Progestogens with Oestrogens. This compound structure is distinct from Progestogen-only pills because it utilizes two types of synthetic hormones working in concert, a design that is clinically recognized for its reliability in preventing conception. The combined use of these synthetic components is a reliable reversible method of contraception.

What are the Active Ingredients in Eloine?

The active core of the medicine is comprised of the synthetic Progestogen Drospirenone and the synthetic Oestrogen Ethinyl Estradiol. This formulation is delivered as film-coated tablets designed for oral administration and is categorized as a combination product. The medicine is a low-dose formulation, specifically containing 0.02 mg of Ethinyl Estradiol, a characteristic that differentiates it from older combined pills. The product is presented in a 28-day cycle, consisting of 24 hormone-containing active tablets followed by four inactive placebo tablets.

What Makes Drospirenone and Ethinyl Estradiol Unique?

The progestin Drospirenone has unique pharmacological properties, including demonstrated antiandrogenic activity and antimineralocorticoid activity. The combination of Drospirenone and low-dose Ethinyl Estradiol is characterized by pharmacological research for its specific profile. This specific progestogen provides additional benefits by potentially counteracting certain symptoms linked to hormone-induced fluid retention, distinguishing it from contraceptives using alternative progestins. This unique combination allows for a distinct therapeutic profile compared to other contraceptives in the Combined Oral Contraceptive category.

Regulatory References

  1. NIH/NCBI StatPearls: Oral Contraceptive Pills

What side effects are possible with Eloine?

Possible Side Effects and Safety Information

The official safety profile of Eloine (Drospirenone and Ethinyl Estradiol) is defined by its adverse reactions, categorized by their incidence rate in clinical trials and grouped by the body system affected.


Adverse Reaction Scope

Classification Examples (As Per Regulatory Labeling)
Very Common (ge 10%) Headache, including Migraine.
Common (ge 1% to < 10%) Nausea, Breast pain/tenderness, Menstrual irregularities, Mood changes (Affect lability), Decreased libido, and Weight increase.

Adverse effects are documented across several System-Organ Classes, including Vascular Disorders, Reproductive System and Breast Disorders, Nervous System Disorders, and Hepatobiliary Disorders.


Serious Adverse Reactions and Safety Constraints

The medication is officially associated with the risk of Serious Adverse Reactions, including Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as Arterial Thromboembolism (ATE) (e.g., Stroke or Myocardial Infarction).

Due to the anti-mineralocorticoid activity of Drospirenone, there is a documented risk of Hyperkalemia (high potassium levels), which necessitates contraindication in patients with renal impairment, hepatic impairment/liver disease, or adrenal insufficiency.

Time- or exposure-related patterns documented in regulatory text indicate that the risk of VTE is highest during the first year of initial use or upon restarting the medication after a break of four weeks or more.

Use is also contraindicated in women over the age of 35 who smoke, and those with a history of hormone-sensitive cancers or pre-existing thrombotic diseases.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Eloine (Drospirenone and Ethinyl Estradiol) define the overdose profile based on its classification as having low acute toxicity. Acute ingestion has generally not been associated with serious ill effects in regulatory safety data.

Overdose Scope

Feature Official Regulatory Statement
Documented Manifestations Overdose may present with nausea, vomiting, and vaginal bleeding (or withdrawal bleeding).
Exposure-Related Factors Serious ill effects following ingestion of large doses by children have generally not been reported.
Emergency-Response Statement Seek immediate medical attention or contact a Poison Control Center for guidance.
When Help is Required Medical advice must be sought immediately following a suspected or confirmed overdose.

Management and Treatment

  • Antidote Information: No specific antidote is known for this combined hormonal contraceptive formulation.
  • Supportive Measures: Treatment must be strictly symptomatic and supportive in nature.
  • Monitoring Notes: No specific monitoring protocols or population-specific considerations (e.g., for hepatic or renal impairment) are explicitly detailed in the official overdose sections.

Connection to the Overall Overdose Profile The regulatory documents confirm the low acute toxicity and limited clinical manifestations expected from overdose. This profile mandates that immediate medical help be sought for professional evaluation, as the lack of a known specific antidote restricts procedural intervention to general symptomatic and supportive measures.

Therapeutic Uses of Eloine

What Eloine Treats: Main Uses and Benefits

The primary therapeutic use of Eloine (Drospirenone and Ethinyl Estradiol) is for pregnancy prevention for women of reproductive potential. The combination tablet is commonly used in clinical settings that involve three distinct therapeutic applications: pregnancy prevention, addressing severe Premenstrual Dysphoric Disorder (PMDD), and assisting with moderate acne vulgaris.

The medication is commonly used to help address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and those that interfere with daily functioning, associated with PMDD. This provides supportive relief when symptoms interfere with routine activities and generally helps improve day-to-day comfort.


Quick Fact: Relevant for Managing Severe Cyclic Distress

The specific formulation is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability for conditions characterized by periods of heightened emotional and physical symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Eloine? Official Regulatory Information

Official regulatory documents define the strict population eligibility for Eloine (Drospirenone and Ethinyl Estradiol) through a series of absolute contraindications and use restrictions.

Populations and Conditions Prohibited from Use

Use is strictly contraindicated in females with a high risk of blood clots, which includes those with a current or history of venous or arterial thromboembolic events (such as DVT, PE, stroke, or heart attack) or certain hereditary clotting disorders. This prohibition also applies to females over 35 who smoke, due to a significantly elevated cardiovascular risk, and those with uncontrolled or severe hypertension.

Further contraindications include severe hepatic disease or liver tumors, severe renal insufficiency (or adrenal insufficiency), and known or suspected sex-steroid influenced malignancies (e.g., breast cancer). The medicine must be discontinued immediately if pregnancy occurs, as it is contraindicated during this period.

Age and Conditional Eligibility

Category Regulatory Status
Age Group Use is established in females post-menarche and is not indicated after menopause.
Lactation Not recommended during breastfeeding.
Postpartum Use Must not be started until 4 weeks after delivery (if not breastfeeding).

What should I know about interactions with other medicines?

The official regulatory profile for Eloine (Drospirenone and Ethinyl Estradiol) is defined by pharmacokinetic and pharmacodynamic interactions that result in specific restrictions and prohibitions.

Co-administration is contraindicated with certain Hepatitis C drug regimens, specifically combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented potential for significant liver enzyme elevation. Cigarette smoking is also a formal contraindicated substance interaction in females aged 35 years and older due to the risk of serious cardiovascular events.

Significant drug–drug interactions involve the CYP3A4 metabolic pathway. Strong CYP3A4 inhibitors, such as specific azole antifungals (e.g., ketoconazole, itraconazole), can increase the plasma concentration of Drospirenone. Conversely, CYP enzyme inducers may reduce the medicine's effectiveness and increase breakthrough bleeding.

Due to Drospirenone’s anti-mineralocorticoid activity, a pharmacodynamic interaction occurs with medications that raise serum potassium concentration, including potassium-sparing diuretics, ACE inhibitors, ARBs, and long-term NSAIDs. This combination increases the risk of hyperkalemia, and for this reason, the use of Eloine is contraindicated in patients with pre-existing renal impairment or adrenal insufficiency.

Regarding other products, Grapefruit juice may increase the blood levels of the Ethinyl Estradiol component. Additionally, a required procedural constraint mandates cessation of the medicine at least four weeks before and through two weeks after major surgery.

Mechanism of Action

Eloine is a fixed-dose combination of ethinyl estradiol and drospirenone. The primary mechanism involves modulation of the hypothalamic-pituitary-ovarian (HPO) axis.

Ethinyl estradiol, a synthetic estrogen, and drospirenone, a synthetic progestin and spironolactone analog, exert negative feedback on the hypothalamus and anterior pituitary gland. This interaction suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH), which, in turn, diminishes the pituitary's secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

This downstream suppression of gonadotropins prevents follicular maturation and the LH surge, a molecular event required for ovulation (the release of an oocyte from the ovary). Additionally, drospirenone acts as a potent agonist at the progesterone receptor and an antagonist at the androgen and mineralocorticoid receptors (MR). Its progestogenic activity modifies the cervical mucus, increasing its viscosity, and alters the endometrium, transforming it from a proliferative to a secretory state. The antimineralocorticoid activity, due to MR antagonism, leads to a mild increase in sodium and water excretion.

Dosage and Administration Information

Administration Guidelines

Eloine (Drospirenone 3 mg / Ethinyl Estradiol 0.02 mg) is administered through the oral route as film-coated tablets, according to a strict 28-day cycle. The dosing regimen involves one tablet daily for 28 consecutive days, ensuring continuous use without a separate pill-free interval.


Procedural Structure and Schedule

Category Instruction Detail
Dosing Schedule Take one tablet daily for 28 days, strictly following the sequence indicated on the blister pack.
Cycle Composition The cycle consists of 24 active hormone tablets followed by 4 inactive (placebo) tablets.
Timing & Conditions The tablet must be taken at about the same time every day. It may be taken with or without food and with a little liquid if necessary.
Pack Transition A new 28-day pack must be started the day immediately following the last tablet of the previous pack, without interruption.
Age Group Use The regimen applies to postpubertal adolescents; use is not indicated before menarche.
Missed Dose Rule Specific protocols are detailed for handling missed active tablets, based on the time elapsed and the week of the cycle.

The instructions for continuous daily adherence and sequential tablet-taking define the standardized protocol for the medication. This 24/4 cyclic structure, with a precise daily timing, is the basis of the administration framework.

Recent Clinical Evidence

Eloine: Recent Clinical Evidence

Eloine is a combined oral contraceptive that contains low-dose ethinylestradiol (an estrogen) and drospirenone (a progestogen). Clinical research has primarily focused on the effectiveness of the 24-day active regimen (24/4 cycle) and the associated risk profiles.


Contraceptive Efficacy

Studies evaluating the prevention of pregnancy (contraceptive efficacy) have consistently reported low failure rates when the product is used correctly. One large US observational study noted lower failure rates with the 24/4 ethinylestradiol/drospirenone regimen compared to a traditional 21-day active regimen of the same hormones.

Non-Contraceptive Indications

The formulation has been evaluated in clinical trials for its use beyond contraception. It is also authorized for the treatment of moderate acne vulgaris in women seeking oral contraception, and for the treatment of symptoms of Premenstrual Dysphoric Disorder (PMDD) in women who choose oral contraception as their birth control method. The efficacy for PMDD was typically assessed over short-term periods (e.g., three cycles).

Safety and Thromboembolic Risk

Research regarding safety, consistent with other combined oral contraceptives (CHCs), indicates an association with a slightly increased risk of venous thromboembolism (VTE). This risk is highest during the first year of use or when restarting the medication after a break of four weeks or more. Epidemiological studies have suggested that the VTE risk associated with drospirenone-containing CHCs is higher compared to CHCs containing older progestogens like levonorgestrel.

Key Studies & References

  1. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies
  2. Combined hormonal contraceptives and venous thromboembolism: review confirms risk is small (GOV.UK / MHRA Drug Safety Update)

Frequently Asked Questions (FAQ)

Common questions about Eloine (FAQ)

Q: Why is Eloine prescribed for acne?

Official product information indicates that Eloine is approved for treating moderate acne vulgaris in women who are also seeking an oral contraceptive. This is partly due to the specific properties of the hormone drospirenone, which has a known antiandrogenic effect. This antiandrogenic activity can help counteract the effects of certain male hormones that contribute to acne development.


Q: How quickly does Eloine start working for contraception?

According to the official administration guidance, if the medicine is started on the first day of the menstrual period, contraceptive protection is usually considered immediate. However, if the start date is later (up to Day 5 of the period), a non-hormonal back-up method is required for use during the first seven consecutive days of active tablet taking.


Q: Can Eloine impact my sleep patterns?

Sleep disturbance or poor sleep has been reported in clinical contexts related to hormonal contraception, though it is not listed as a very common side effect in the official documents. Such effects may sometimes be associated with mood changes that are noted as a common side effect of the medicine.


Q: Is there a link between Eloine and changes in appetite?

While regulatory documents list weight increase as a common side effect, a direct link to changes in appetite (either increased or decreased) is not frequently reported as an adverse reaction in the official product information.


Q: How long does it take for side effects to typically go away after starting Eloine?

Common temporary side effects, such as nausea or irregular bleeding (spotting), are commonly reported to subside within the first two to three months of continuous use. This period is when the body is expected to adjust to the new hormonal balance.


Q: How is Eloine different from Yasmin or Yaz?

Eloine contains the same two active hormones, drospirenone and ethinyl estradiol, as Yasmin and Yaz. The difference is that Eloine is a low-dose formulation, containing a lower amount of ethinyl estradiol than the original Yasmin formulation.


Q: Does Eloine have the same active ingredients as other drospirenone/ethinylestradiol pills?

Yes, Eloine contains the synthetic hormones drospirenone and ethinyl estradiol. However, it is important to know that while other oral contraceptives may share these active ingredients, they may be offered at a different dosage of ethinyl estradiol.


Q: What is the difference between the active and inactive tablets in the Eloine pack?

The blister pack consists of 24 active tablets which contain the two hormones. The remaining 4 tablets are inactive (placebo) and contain no active hormones. The inactive tablets are included solely to help maintain the daily habit and ensure the new pack is started on time.


Q: Can I start taking Eloine at any point in my menstrual cycle?

Official guidance recommends that to ensure immediate contraceptive protection, the first active tablet should be taken on Day 1 of the menstrual period. If the medicine is started later (up to Day 5), the use of a back-up, non-hormonal method is necessary for the first seven days.


Q: What if I vomit shortly after taking an Eloine tablet?

The official documentation states that if vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active tablet, the hormones may not have been fully absorbed. In this situation, regulatory guidance indicates that the procedure for a missed tablet should be followed.


Q: Is it normal to not have a period while taking the inactive tablets of Eloine?

The absence of a withdrawal bleed (amenorrhea) is a known occurrence, particularly with low-dose regimens like Eloine. If the period does not occur, especially for two consecutive cycles, official guidance requires that the possibility of pregnancy be evaluated by a healthcare provider.


Q: Does Eloine affect fertility after I stop taking it?

Current medical evidence does not indicate that the use of combined oral contraceptives affects a woman's ability to become pregnant in the long term. Fertility typically returns to pre-treatment levels within a few months after the medicine is discontinued.


Q: How is the acne-improving effect of Eloine described in studies?

Clinical studies have examined the regimen for its ability to treat moderate acne vulgaris. The evidence indicates that study participants experienced a reduction in both inflammatory and non-inflammatory lesions in women who are seeking oral contraception.


Q: Are there specific checks required before starting treatment with Eloine?

Regulatory guidelines indicate that prescribing requires the assessment of a thorough medical history, including family history of blood clots, and the recording of a blood pressure measurement before a person initiates use of any combined oral contraceptive.


Q: What should I do if I think I'm experiencing a severe side effect from Eloine?

If symptoms of a serious adverse reaction, such as a blood clot (e.g., severe leg pain, sudden shortness of breath), are suspected, official patient information states that the medication must be discontinued and immediate emergency medical attention is required.


Q: Is there evidence that Eloine helps reduce premenstrual symptoms (PMS)?

Official indications state that Eloine is specifically studied and authorized for the treatment of symptoms of Premenstrual Dysphoric Disorder (PMDD) in women who choose the pill for birth control. PMDD is recognized as a more severe condition than general Premenstrual Syndrome (PMS).


Q: Is Eloine gluten-free or lactose-free?

The official drug labeling lists the inactive components, known as excipients. The active tablets of Eloine typically contain lactose monohydrate, meaning the product is not lactose-free. Official documentation does not typically provide a statement regarding the gluten-free status of the tablet.


Q: Do I need to use an additional form of contraception when starting Eloine?

If the medicine is started after the first day of the menstrual period, an additional non-hormonal method is necessary for the first seven consecutive days of active tablet taking.


Q: Can Eloine change the appearance of my skin, besides treating acne?

Hormonal contraceptives are officially associated with a risk of developing melasma, which involves dark, irregular patches on the skin. Regulatory text includes a precaution that women prone to melasma should limit or avoid exposure to the sun or ultraviolet light while using the medicine.


Q: Where can I find the official patient information leaflet (PIL) for Eloine?

The official Patient Information Leaflet (PIL), or the more technical Summary of Product Characteristics (SmPC), can be found on the public websites of national regulatory authorities. Examples include the European Medicines Agency (EMA) or the FDA DailyMed/Labeling section.


Q: Are there specific vitamins or supplements that are not recommended with Eloine?

Official drug interaction information advises caution with any medication or supplement that can raise serum potassium levels. Additionally, information on use with a strong CYP3A4 enzyme inducer should be reviewed with a healthcare provider due to the risk of reduced effectiveness.


Q: Can I use Eloine if I have high blood pressure?

Use of the medicine is contraindicated (not allowed) in women with uncontrolled hypertension or high blood pressure associated with blood vessel damage. However, regulatory documents state that women with adequately controlled hypertension require close monitoring if the medicine is used.


Q: Does Eloine have a known effect on cholesterol levels?

Official information notes that combined oral contraceptives can affect lipid metabolism, which includes cholesterol and triglyceride levels. For women with pre-existing or uncontrolled abnormal lipid levels (dyslipidemia), an alternate contraceptive method may be considered.


Q: Can I use Eloine if I have had a history of depression?

Women with a history of depression are advised in regulatory documents to be carefully monitored while taking the medicine. Regulatory documents state that discontinuation of the medication is required if depression recurs or worsens to a serious degree.


Q: What is the shelf life of Eloine tablets?

The shelf life of the tablets is typically stated in the official product information as 3 years from the date of manufacture. The definitive expiry date is always printed on the original packaging of the product.


Q: Does Eloine interact with herbal supplements like St. John's Wort?

Yes, the herbal supplement St. John's Wort (Hypericum perforatum) is explicitly listed in regulatory documents as an interaction risk. This supplement may reduce the effectiveness of hormonal contraceptives and lead to breakthrough bleeding. The concurrent use of the supplement necessitates the use of an alternative or additional contraceptive method.

How should Eloine be stored and disposed of?

Storage Conditions and Environment

The official regulatory documents specify that Eloine must be stored at a Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), and should not be stored above 30 C (86 F). The product must be stored in its original container to protect the tablets from both light and moisture. Furthermore, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Eloine must be disposed of according to local requirements for pharmaceutical waste. Regulatory instructions strictly state that this medicine must not be discarded via wastewater or household waste. Disposing of the product via local take-back programs or by consulting a pharmacist helps prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eloine found in:

A-Z Index: